Get the Stockscreener App
7.0414
1.12%
-0.0886
Valneva Se Adr stock is traded at $7.0414, with a volume of 138.63K.
It is down -1.12% in the last 24 hours and up +41.00% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$7.13
Open:
$7.18
24h Volume:
138.63K
Relative Volume:
1.86
Market Cap:
$721.99M
Revenue:
$180.81M
Net Income/Loss:
$-160.71M
P/E Ratio:
-3.7596
EPS:
-1.8729
Net Cash Flow:
$-88.46M
1W Performance:
+33.02%
1M Performance:
+41.00%
6M Performance:
-34.54%
1Y Performance:
-38.86%
1-Day Range:
$7.05
$7.30
1-Week Range:
$5.44
$7.31
52-Week Range:
$4.75
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
7.07 | 728.11M | 180.81M | -160.71M | -88.46M | -1.8729 |
VRTX
Vertex Pharmaceuticals Inc
|
515.52 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.26 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.16 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Goldman | Neutral → Sell |
| Aug-19-25 | Resumed | H.C. Wainwright | Buy |
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application - Sahm
Valneva (NASDAQ:VALN) Sees Strong Trading VolumeWhat's Next? - marketbeat.com
Pfizer, Valneva Lyme vaccine enters EMA review - grafa.com
Valneva SE earnings missed by $0.18, revenue fell short of estimates - Investing.com
Dow Falls Over 100 Points; US Consumer Sentiment Declines In August - Sahm
Valneva Q2 Earnings Call Highlights - Yahoo Finance
Valneva H1 2026 slides: loss widens as Lyme hopes build - Investing.com
Earnings call transcript: Valneva H1 2026 loss widens as Lyme hopes build - Investing.com Nigeria
Valneva (NASDAQ:VALN) Shares Gap UpHere's Why - marketbeat.com
Valneva stock initiated at Buy by TD Cowen on Lyme vaccine potential - Investing.com
Valneva SE Sponsored ADR (NASDAQ:VALN) Receives Consensus Rating of "Hold" from Analysts - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, L - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - The National Law Review
Valneva's Trading Restriction Lifts at an Awkward Moment as Analysts Square Off Over Vaccine Prospec - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - The National Law Review
AYJ0 Forecast — Price Target — Prediction for 2027 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - The National Law Review
A3CPD1 Forecast — Price Target — Prediction for 2027 - TradingView
Valneva SE Sponsored ADR Actuals & Estimates (NASDAQ:VALN) - TradingView
VALN Q1 2026 Earnings: Significant EPS Miss Highlights Development‑Stage Cash BurnEstimate Dispersion - newsline.com
VLA.PA Technical Analysis | Trend, Signals & Chart Patterns | VALNEVA SE (EPA:VLA) - ChartMill
VALNEVA:Declaration of shares and voting rights - GlobeNewswire Inc.
VALN Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclinePreliminary Results - dars.gov.et
VALNValneva SE ADR Stock Price and Quote - Finviz
Valneva (VALN) Holds Steady Near Support as Traders Weigh Near-Term CatalystsMarket Cap Weight - The Legal Advocate
VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Valneva SE earnings missed by $0.24, revenue fell short of estimates - Investing.com
Valneva Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips - Investing.com Nigeria
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
Valneva’s €84M Cash Injection Comes With a Bitter Pill for Shareholders - AD HOC NEWS
Valneva faces securities fraud probe after Lyme vaccine trial misses key goal, shares drop 37%. - Pluang
Law firm probes Valneva over vaccine trial resu... - Pluang
Valneva shares slide after US pullback on chikungunya vaccine filing - MSN
Valneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty - Investing.com
Valneva's Dual Challenge: Legal Scrutiny Meets Commercial Reality - AD HOC NEWS
Guggenheim cuts Valneva stock price target to $11 on Lyme vaccine - Investing.com
Valneva faces investigation after Lyme vaccine trial misses primary goal, shares drop 37%. - Pluang
Valneva SE Under Investigation for Securities Fraud - Intellectia AI
VALN stock nosedives on mixed results from Lyme disease vaccine study - MSN
Law firm investigates Valneva over vaccine tria... - Pluang
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):